Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12608682 | 1.00 | TP53 (0.48) | TP53ADRA2APLK1ACKR3CHRNB2 | |
| SCHEMBL12608662 | 0.85 | TP53 (0.48) | TP53ADRA2AACKR3CHRNB4CHRNA3 | |
| SCHEMBL18500535 | 0.85 | TP53 (0.48) | TP53ADRA2AACKR3CHRNB4CHRNA3 | |
| SCHEMBL12608716 | 0.83 | TP53 (0.76) | TP53ADRA2APLK1CHRNB2CHRNA4 | |
| SCHEMBL15848980 | 0.83 | TP53 (0.63) | TP53ADRA2APLK1ACKR3CHRM3 | |
| SCHEMBL13418930 | 0.83 | TP53 (0.76) | TP53ADRA2APLK1CHRNB2CHRNA4 | |
| SCHEMBL14548994 | 0.80 | TP53 (0.44) | TP53ADRA2AACKR3CHRNB4CHRNA3 | |
| SCHEMBL12608655 | 0.79 | TP53 (0.71) | TP53ADRA2APLK1CHRNB2CHRNA4 | |
| SCHEMBL18500521 | 0.79 | TP53 (0.71) | TP53ADRA2APLK1CHRNB2CHRNA4 | |
| SCHEMBL18500469 | 0.79 | TP53 (0.71) | TP53ADRA2APLK1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | TP53 28/4885ADRA2A 3619/4885PLK1 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.